DisGeNET
IMIM / DisGeNET (commercial entity)
Comprehensive gene-disease and variant-disease association database. >2M GDAs, >4M VDAs, >20M DDAs. Integrates curated repositories, GWAS, animal models, and NLP-extracted evidence.
Best For
Genetic evidence for target validation; disease similarity analysis
License
Academic free; Commercial license required
Strengths
- +>2M gene-disease associations
- +GDA scoring
- +REST API and R package
Limitations
- −Commercial license required for pharma
- −NLP-extracted evidence has false positives
R&D Pipeline Coverage
Related Tools
Open Targets Platform
EBI / Genentech / GSK / MSD / Pfizer / Sanofi / Wellcome Sanger
Integrates 23+ public data sources to systematically score and rank target-disease associations. Provides target prioritization based on clinical precedence and tractability.
STRING v12.5
EMBL / SIB / CPR
Functional protein-protein association networks across 12,535 organisms. v12.5 added a regulatory network layer capturing directionality via LLM-parsed literature.
More in Target Discovery
Open Targets Platform
EBI / Genentech / GSK / MSD / Pfizer / Sanofi / Wellcome Sanger
Integrates 23+ public data sources to systematically score and rank target-disease associations. Provides target prioritization based on clinical precedence and tractability.
STRING v12.5
EMBL / SIB / CPR
Functional protein-protein association networks across 12,535 organisms. v12.5 added a regulatory network layer capturing directionality via LLM-parsed literature.
ChEMBL v35
EMBL-EBI
Manually curated bioactivity database. 5.4M+ bioactivity measurements for 1M+ compounds against 5,200+ protein targets from peer-reviewed literature.
Stay updated on DisGeNET
Weekly newsletter covering AI tool releases, benchmarks, and what practitioners actually use.